Evidence map›Paper›PMID 41966730›Full record

ArticleEBioMedicine2026

Biomarkers of Alzheimer's disease pathophysiology and delirium.

Kristi Henjum, Bjørn Erik Neerland, Kaj Blennow, Henrik Zetterberg, Christian Thomas Pollmann, Roy Bjørkholt Olsen, Lene Solberg, Marius Myrstad, Olav Tobias Ødegaard, Adi Karabeg and 3 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in EBioMedicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Kristi HenjumOslo Delirium Research Group, Institute of Clinical Medicine, University of Oslo, 0318, Oslo, Norway.
Bjørn Erik NeerlandOslo Delirium Research Group, Institute of Clinical Medicine, University of Oslo, 0318, Oslo, Norway; Department of Geriatric Medicine, Oslo University Hospital, 0424, Oslo, Norway.
Kaj BlennowDepartment of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, The Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden; Clinical Neurochemistry Laboratory, Sahlgrenska University Hospital, Mölndal, Sweden; Paris Brain Institute, ICM, Pitié-Salpêtrière Hospital, Sorbonne University, Paris, France; Neurodegenerative Disorder Research Center, Division of Life Sciences and Medicine, Department of Neurology, Institute On Aging and Brain Disorders, University of Science and Technology of China and First Affiliated Hospital of USTC, Hefei, PR China.
Henrik ZetterbergDepartment of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, The Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden; Clinical Neurochemistry Laboratory, Sahlgrenska University Hospital, Mölndal, Sweden; Department of Neurodegenerative Disease, UCL Institute of Neurology, London, UK; UK Dementia Research Institute at UCL, London, UK; Hong Kong Center for Neurodegenerative Diseases, Hong Kong Special Administrative Region of China; Wisconsin Alzheimer's Disease Research Center, University of Wisconsin School of Medicine and Public Health, University of Wisconsin-Madison, Madison, WI, USA.
Christian Thomas PollmannDepartment of Orthopedic Surgery, Akershus University Hospital, Oslo, Norway.
Roy Bjørkholt OlsenDepartment of Anesthesiology and Intensive Care, Sørlandet Hospital, Arendal, Norway.
Lene SolbergDivision of Orthopaedic Surgery, Oslo University Hospital, 0424, Oslo, Norway.
Marius MyrstadDepartment of Internal Medicine, Bærum Hospital, Vestre Viken Hospital Trust, Bærum, Norway.
Olav Tobias ØdegaardDepartment of Anesthesiology, Akershus University Hospital, Kongsvinger, Norway.
Adi KarabegDepartment of Orthopedic Surgery, Akershus University Hospital, Kongsvinger, Norway.
Alan GulestølDepartment of Anaesthesiology, Oslo University Hospital, Oslo, Norway.
Ane Victoria IdlandOslo Delirium Research Group, Institute of Clinical Medicine, University of Oslo, 0318, Oslo, Norway; Department of Anaesthesiology, Akershus University Hospital, Norway.
Leiv Otto WatneOslo Delirium Research Group, Institute of Clinical Medicine, University of Oslo, 0318, Oslo, Norway; Department of Geriatric Medicine, Akershus University Hospital, 1478, Lørenskog, Norway. Electronic address: l.o.watne@medisin.uio.no.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundAlzheimer's disease (AD) is characterised by amyloid-beta (A) and tau (T) pathology, and neurodegeneration (N). AT(N) neuropathology precedes the symptomatic presentation of the disease. This asymptomatic phase may present vulnerability towards delirium, but studies are inconclusive. In this cross-sectional study of hip fracture patients, we aimed to explore the association between AD biomarkers for AT(N) neuropathology and delirium, with focus on patients without clinical dementia.

methodsThe AT(N) biomarkers were analysed in cerebrospinal fluid (CSF) in hip fracture patients (n = 401). Pre-fracture dementia was defined by IQCODE ≥3.44 (n = 164). Delirium was diagnosed according to the DSM-5 criteria. The CSF concentrations of amyloid-beta

findingsHip fracture patients with delirium had lower CSF Aβ42 concentrations and higher concentrations of CSF p-tau and CSF t-tau than those without delirium (student's t-test, all p-values <0.001). Brain Aβ-deposition, A+ was more common in patients with delirium (χ

interpretationThese findings support that the AD AT neuropathology is a risk factor for delirium in patients without clinical dementia.

fundingSouth-Eastern Norway Regional Health Authorities (# 2017095), the Norwegian Health Association (#16149, #19536, #1513) and by Wellcome Leap's Dynamic Resilience Program (jointly funded by Temasek Trust) (#104617).

Indexed as

Alzheimer DiseaseBiomarkersDeliriumAgedAged, 80 and overAmyloid beta-PeptidesCross-Sectional StudiesFemaleHip FracturesHumansMalePeptide Fragmentstau ProteinsAmyloid beta-PeptidesBiomarkersPeptide Fragmentstau ProteinsAcute hip fractureAlzheimer's diseaseCSF biomarkersDeliriumDementia

Identifiers

PMID41966730
PMCPMC13091946

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.